Shares of Adyen (ADYEN.NL) are gaining nearly 21% in today's session after the company reported better-than-expected processed volumes and net income in the second half of the year, offering relief after surprisingly weak first-half results. Ebitda margin exceeded analysts' estimates, as the company boosted profitability by slowing hiring.
SECOND-HALF RESULTS
- Net revenues €887 million, +23% y/y, estimated at €875.5 million
- Net revenues in North America €242.0 million, +27% y/y, estimated €236.1 million
- Net revenues in the APAC region €98.0 million, +25% y/y, estimated €116.5 million
- Net revenues in the EMEA region €491.0 million, +23% y/y, estimated €476.6 million
- Revenues €1.01 billion, -80% y/y, estimated €981.2 million
- Processing fees €251.2 million, +21% y/y, estimated €246.7 million
- Settlement fees €596.2 million, -87% y/y, estimated €974.4 million
- Ebitda margin 48%, estimated 44.1%
- Ebitda €423 million, +14% y/y, estimated €388.9 million
- Processed volumes €544.1 billion, +29% y/y, estimated €514.33 billion
- Net profit €416.1 million, +48% y/y, estimated €343 million
- Operating profit €378.5 million, +13% y/y, estimated €340.4 million
- Profit before tax €569.6 million, +58% y/y, estimated €437.9 million
- Costs incurred by financial institutions €73.4 million, -98% y/y, estimated €100 million
- Costs of goods sold €49.5 million, +72% y/y, estimated €43.6 million
- Diluted earnings per share €13.36 million vs. €9.08 million y/y, estimated €11.00 million
- Free cash flow €391.8 million, +31% y/y, estimated €341.7 million
The company is steadily increasing its net income. Source: Bloomberg Financial LP
Adyen shares began today's trading with a sharp upward gap, which with its range touched the resistance zone set by the 38.2% Fibo retracement and the local lows of July and August 2023. Source: xStation
Goldman Sachs boosts sentiment on Estée Lauder shares 💡
US OPEN: "Green" Start to the Week on Wall Street
OpenAI Announces Partnership with Broadcom. Company Shares Soar!
DE40: Europe's markets recovering from correction
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
